• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp.

    9/8/21 4:22:18 PM ET
    $AHAC
    Business Services
    Finance
    Get the next $AHAC alert in real time by email
    SC 13G 1 schedule13g.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

     
    SCHEDULE 13G

     
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No.___)*
     

     
    HUMACYTE, INC.
    (Name of Issuer)

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

    44486Q103
    (CUSIP Number)

    August 26, 2021
    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☐
    Rule 13d-1(b)
      ☒
    Rule 13d-1(c)
      ☐
    Rule 13d-1(d)




    *            The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
     
    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
    PTC Trustees GY Limited as Trustee of The GYF Trust
     
    2
     
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ◻
     
    (b) ◻
     
    3
     
    SEC USE ONLY
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Cyprus
     
     
    NUMBER OF SHARES BENEFICIA-LLY OWNED BY EACH REPORTING PERSON WITH
    5
     
    SOLE VOTING POWER
    0 shares of Common Stock
     
    6
     
    SHARED VOTING POWER
    8,942,078 shares of Common Stock
     
    7
     
    SOLE DISPOSITIVE POWER
    0 shares of Common Stock
     
    8
     
    SHARED DISPOSITIVE POWER
    8,942,078 shares of Common Stock
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    8,942,078 shares of Common Stock
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)                                                                                                                                             ◻
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    8.7%(1)
     
    12
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO
     
     
    (1)
    Based upon 103,003,384 shares of the Issuer’s Common Stock outstanding as of August 26, 2021, as reported in the Issuer’s Current Report on Form 8-K (the “Form 8-K”) filed with the Securities and Exchange Commission (the “SEC”) on August 27, 2021.
       
     



    1
     
    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
    Gavril Abramovich Yushvaev
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a) ◻
     
    (b) ◻
     
    3
     
    SEC USE ONLY
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Russian and Israeli
     
     
    NUMBER OF SHARES BENEFICIA-LLY OWNED BY EACH REPORTING PERSON WITH
    5
     
    SOLE VOTING POWER
    0 shares of Common Stock
     
    6
     
    SHARED VOTING POWER
    8,942,078 shares of Common Stock
     
    7
     
    SOLE DISPOSITIVE POWER
    0 shares of Common Stock
     
    8
     
    SHARED DISPOSITIVE POWER
    8,942,078 shares of Common Stock
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     8,942,078 shares of Common Stock
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ◻
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    8.7%(1)
     
    12
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IN
     
     
    (1)
    Based upon 103,003,384 shares of the Issuer’s Common Stock outstanding as of August 26, 2021, as reported in the Issuer’s Current Report on Form 8-K (the “Form 8-K”) filed with the Securities and Exchange Commission (the “SEC”) on August 27, 2021.
     
     
    [The remainder of this page intentionally left blank.]
     
       



    Item 1.                                   (a)            Name of Issuer:

    Humacyte, Inc., a Delaware corporation, formerly known as Alpha Healthcare
    Acquisition Corp. (the “Issuer”).

                                  (b)     Address of Issuer’s Principal Executive Offices:

    2525 East North Carolina Highway 54, Durham, NC 27713

    Item 2.          (a)     Name of Person Filing:

    This statement is being filed pursuant to a Joint Filing Agreement (attached as Exhibit 1 and incorporated herein by reference) between (i) PTC Trustees GY Limited as Trustee of The GYF Trust a trust established under the laws of Cyprus, and (ii) Gavril Abramovich Yushvaev (sometimes collectively referred to as the “Reporting Persons”).  Gavril Abramovich Yushvaev is a Russian and Israeli citizen. PTC Trustees GY Limited is a Cyprus company.

    (b)            Address of Principal Business Office or, if none, Residence:

    The address of the business office of PTC Trustees GY Limited as Trustee of The GYF Trust is Anastasios Leventis 5, Leventis Gallery Tower, 8th Floor, 1097 Nicosia, Cyprus. The business address for Mr. Gavril Abramovich Yushvaev is c/o PTC Trustees GY Limited, Anastasios Leventis 5, Leventis Gallery Tower, 8th Floor, 1097 Nicosia, Cyprus.

    (c)            Citizenship:

    See Item 2(a) above.

    (d)            Title of Class of Securities:

    Common Stock, par value $0.0001 per share (the “Common Stock”)

    (e)            CUSIP Number:

    44486Q103


    [The remainder of this page intentionally left blank.]



    Item 3.                          If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check whether the Person Filing is:


    (a)             ◻ Broker or dealer registered under Section 15 of the Act;


    (b)             ◻ Bank as defined in Section 3(a) (6) of the Act;


    (c)             ◻ Insurance company as defined in Section 3(a) (19) of the Act;


    (d)             ◻ Investment company registered under Section 8 of the Investment Company Act;


    (e)             ◻ An investment adviser in accordance with Rule 13d-1(b) (1) (ii) (E);


    (f)             ◻ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b) (1) (ii) (F);


    (g)             ◻ A parent holding company or control person in accordance with Rule 13d-1(b) (1) (ii) (G);


    (h)             ◻ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;


    (i)             ◻ A church plan that is excluded from the definition of an investment company under Section 3(c) (14) of the Investment Company Act;


    (j)             ◻ Group, in accordance with Rule 13d-1(b) (1) (ii) (J).

    Not applicable.

    Item 4.       Ownership.

    PTC Trustees GY Limited as Trustee of The GYF Trust is the owner of 8,942,078 shares of Common Stock. Mr. Gavril Abramovich Yushvaev has voting and dispositive power over the shares held by PTC Trustees GY Limited as Trustee of The GYF Trust and, accordingly, is deemed to beneficially own these 8,942,078 shares of Common Stock.

    The following sets forth in tabular format the share ownership as to each of the Reporting Persons:

    (a)            Amount beneficially owned:

    8,942,078 shares of Common Stock

    (b)            Percent of class:

    8.7%

    (c)            Number of shares as to which the person has:

    (i)              Sole power to vote or to direct the vote:

    0 shares of Common Stock

    (ii)              Shared power to vote or to direct the vote:

    8,942,078 shares of Common Stock

    (iii)              Sole power to dispose or to direct the disposition of:

    0 shares of Common Stock

    (iv)              Shared power to dispose or to direct the disposition of:

    8,942,078 shares of Common Stock

    The percentage ownership was calculated based upon 103,003,384 shares of the Issuer’s Common Stock outstanding as of August 26, 2021, as reported in the Form 8-K filed with the SEC on August 27, 2021.

    Item 5.     Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Not applicable.

    Item 6.   Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

    Item 8.    Identification and Classification of Members of the Group.

    Not applicable.

    Item 9.    Notice of Dissolution of Group.

    Not applicable.

    Item 10. Certifications.

    Not applicable.


    [The remainder of this page intentionally left blank.]

    SIGNATURE

    After reasonable inquiry and to the best of the knowledge and belief of each of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.


    Date:  September 08, 2021


    PTC TRUSTEES GY LIMITED AS TRUSTEE OF THE GYF TRUST


    By:            \s\ Svetlana Colta
    Name:  Svetlana Colta
    Title:    Director


    By:            \s\ Stella Kammitsi
    Name:  Stella Kammitsi
    Title:    Director



    \s\ Gavril Abramovich Yushvaev                                                                      
    Gavril Abramovich Yushvaev



    Get the next $AHAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHAC

    DatePrice TargetRatingAnalyst
    7/20/2021$18.00Buy
    Benchmark
    7/20/2021$18.00Buy
    The Benchmark Company
    More analyst ratings

    $AHAC
    SEC Filings

    View All

    SEC Form S-1 filed by Alpha Healthcare Acquisition Corp.

    S-1 - Humacyte, Inc. (0001818382) (Filer)

    9/17/21 4:59:30 PM ET
    $AHAC
    Business Services
    Finance

    Alpha Healthcare Acquisition Corp. filed SEC Form 8-K: Leadership Update

    8-K - Humacyte, Inc. (0001818382) (Filer)

    9/2/21 12:20:03 PM ET
    $AHAC
    Business Services
    Finance

    Alpha Healthcare Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Financial Statements and Exhibits, Leadership Update, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure

    8-K - Humacyte, Inc. (0001818382) (Filer)

    8/27/21 9:01:49 PM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Benchmark initiated coverage on Alpha Healthcare with a new price target

    Benchmark initiated coverage of Alpha Healthcare with a rating of Buy and set a new price target of $18.00

    7/20/21 7:58:11 AM ET
    $AHAC
    Business Services
    Finance

    The Benchmark Company initiated coverage on Alpha Healthcare Acquisition Corp. with a new price target

    The Benchmark Company initiated coverage of Alpha Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $18.00

    7/20/21 7:16:19 AM ET
    $AHAC
    Business Services
    Finance

    Lake Street initiated coverage on Alpha Healthcare Acquisition Corp. with a new price target

    Lake Street initiated coverage of Alpha Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $20.00

    4/9/21 8:42:45 AM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    Leadership Updates

    Live Leadership Updates

    View All

    Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

    Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under "HUMA" and "HUMAW" on August 27, 2021Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial diseaseCombined company will be led by Laura Niklason, M.D., Ph.D., Founder, President & CEO, and current executive teamKathleen Sebelius appointed Chair of the Board of DirectorsHumacyte to commemorate milestone by ringing Nasdaq closing bell on Monday, August 30, 2021 DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform

    8/26/21 4:05:00 PM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

    Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under "HUMA" and "HUMAW" on August 27, 2021Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial diseaseCombined company will be led by Laura Niklason, M.D., Ph.D., Founder, President & CEO, and current executive teamKathleen Sebelius appointed Chair of the Board of DirectorsHumacyte to commemorate milestone by ringing Nasdaq closing bell on Monday, August 30, 2021 DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform

    8/26/21 4:05:00 PM ET
    $AHAC
    Business Services
    Finance

    Alpha Healthcare Acquisition Corp. Announces Shareholder Approval of Business Combination with Humacyte

    NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (NASDAQ:AHAC) ("AHAC"), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, and all other proposals presented at AHAC's special shareholder's meeting held on August 24, 2021. AHAC shareholders approved the business combination proposal with 99.5% votes in favor of the approximately 61.6% of AHAC votes cast at the meeting. AHAC plans to file the results of the

    8/24/21 12:58:48 PM ET
    $AHAC
    $DMTK
    Business Services
    Finance
    Medical Specialities
    Health Care

    Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels

    In addition to the Company's eight ongoing clinical trials, HAVs have been used in 13 expanded access cases for emergent life- and limb-saving vascular surgeries at seven hospitals across the U.S.Video testimonial features patient who experienced a traumatic leg injury and received the HAV to restore blood flow to her crushed limb DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced today the successful completion of its 13th Expanded Access Program (EAP) implant of its bioengineered blood vessel, the Human Acellular Vessel (HAV), in the U

    8/19/21 7:30:00 AM ET
    $AHAC
    $DMTK
    Business Services
    Finance
    Medical Specialities
    Health Care

    $AHAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Scheessele William John

    4 - Humacyte, Inc. (0001818382) (Issuer)

    10/15/21 3:51:53 PM ET
    $AHAC
    Business Services
    Finance

    SEC Form 4 filed by Binder Gordon M

    4 - Humacyte, Inc. (0001818382) (Issuer)

    10/15/21 3:43:59 PM ET
    $AHAC
    Business Services
    Finance

    SEC Form 4 filed by Brown Emery N.

    4 - Humacyte, Inc. (0001818382) (Issuer)

    10/15/21 3:42:44 PM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp.

    SC 13G - Humacyte, Inc. (0001818382) (Subject)

    9/8/21 4:22:18 PM ET
    $AHAC
    Business Services
    Finance

    SEC Form SC 13D filed by Alpha Healthcare Acquisition Corp.

    SC 13D - Humacyte, Inc. (0001818382) (Subject)

    9/2/21 6:04:40 AM ET
    $AHAC
    Business Services
    Finance

    SEC Form SC 13D filed by Alpha Healthcare Acquisition Corp.

    SC 13D - Humacyte, Inc. (0001818382) (Subject)

    8/27/21 9:14:01 PM ET
    $AHAC
    Business Services
    Finance